- Trials with a EudraCT protocol (3,192)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
3,192 result(s) found for: roche OR chugai OR genentech.
Displaying page 130 of 160.
| EudraCT Number: 2008-005450-20 | Sponsor Protocol Number: 80-82310-98-09026 | Start Date*: 2009-10-29 | |||||||||||
| Sponsor Name:Radboud University Nijmegen Medical Centre, department of Rheumatic Diseases | |||||||||||||
| Full Title: The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid artritis. | |||||||||||||
| Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-001414-15 | Sponsor Protocol Number: REVOLUTION | Start Date*: 2018-07-27 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE | |||||||||||||
| Full Title: Randomized phasE 2 study of Valproic acid in combination with bevacizumab and Oxaliplatin/fLUoropyrimidine regimens in patients with ras-mutated metastaTIc cOlorectal caNcer | |||||||||||||
| Medical condition: patients with ras-mutated metastaTIc colorectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-004982-37 | Sponsor Protocol Number: NBK155/1/2020 | Start Date*: 2021-05-19 | |||||||||||
| Sponsor Name:MEDICAL UNIVERSITY OF GDAŃSK | |||||||||||||
| Full Title: Early rituximab treatment in children with idiopathic nephrotic syndrome Eng. ERICONS - Early RITUXIMAB in Childhood Onset Nephrotic Syndrome | |||||||||||||
| Medical condition: NEPHROTIC SYNDROME | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-001314-24 | Sponsor Protocol Number: 111JC101 | Start Date*: 2009-01-02 | |||||||||||
| Sponsor Name:Biogen Idec Ltd | |||||||||||||
| Full Title: A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) | |||||||||||||
| Medical condition: Progressive Multifocal Leukoencephalopathy (PML) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) ES (Completed) FR (Completed) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-000543-33 | Sponsor Protocol Number: PANIB20140110 | Start Date*: 2014-11-20 | |||||||||||
| Sponsor Name:Antwerp University Hospital | |||||||||||||
| Full Title: An open-label, randomized, controlled, multi-center, Phase II trial comparing Panitumumab versus Bevacizumab in combination with oxaliplatin - 5 FU (FOLFOX) first-line treatment according Ras ... | |||||||||||||
| Medical condition: metastatic unresectable colorectal cancer (mCRC) . | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-002634-24 | Sponsor Protocol Number: MultipleMS | Start Date*: 2017-09-29 |
| Sponsor Name:Karolinska Institutet | ||
| Full Title: MultipleMS – Multiple-omics approach to accelerate personalised medicine in a prospective cohort of newly diagnosed MS and CIS patients. | ||
| Medical condition: Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-005638-20 | Sponsor Protocol Number: CRO-2010-14 | Start Date*: 2011-02-18 | |||||||||||
| Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO | |||||||||||||
| Full Title: Phase III randomized trial of preoperative radiotherapy with an integrated simultaneous boost IMRT-IGRT) versus chemoradiotherapy for T3-4 rectal cancer | |||||||||||||
| Medical condition: Patients with operable rectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-001720-37 | Sponsor Protocol Number: CRO-2011-12 | Start Date*: 2011-12-01 | |||||||||||
| Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO | |||||||||||||
| Full Title: Multi-centre, phase II, single arm study of the docetaxel, oxaliplatin, capecitabine (DOC) combination in untreated patients with advanced or metastatic gastric cancer | |||||||||||||
| Medical condition: patients with metastatic gastric carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-024266-21 | Sponsor Protocol Number: IEOS582/111 | Start Date*: 2011-07-29 | |||||||||||
| Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
| Full Title: A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine and vinorelbine in metastatic breast cancer patients | |||||||||||||
| Medical condition: Metastatic breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-009937-14 | Sponsor Protocol Number: IEO S459/109 | Start Date*: 2009-11-13 | |||||||||||
| Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
| Full Title: Metronomic Capecitabine plus Docetaxel as first line treatment for metastatic breast cancer patients: a phase II trial | |||||||||||||
| Medical condition: Metastatic breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-012048-18 | Sponsor Protocol Number: IEO S479/209 | Start Date*: 2009-07-06 | |||||||||||
| Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
| Full Title: �Fase II study with epirubicin, cisplatin and infusional fluorouracil (ECF) followed by weekly paclitaxel plus metronomic cyclophosphamide � trastuzumab as preoperative treatment of locally adva... | |||||||||||||
| Medical condition: Locally advanced breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-000341-64 | Sponsor Protocol Number: IEO S389/108 | Start Date*: 2008-12-23 | |||||||||||
| Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
| Full Title: EVALUATION OF ACQUIRED OVEREXPRESSION OF HER2/neu ON CIRCULATING TUMOR CELLS IN PATIENTS WITH ADVANCED BREAST CANCER DURING CHEMOTHERAPY, AND ASSESSMENT OF ACTIVITY OF TRASTUZUMAB-BASED THERAPY: A ... | |||||||||||||
| Medical condition: advanced breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-003994-28 | Sponsor Protocol Number: VinCaT | Start Date*: 2006-11-10 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE" | |||||||||||||
| Full Title: VINORELBINE, CARBOPLATIN AND TRASTUZUMAB IN ADVANCED HER-2 POSITIVE BREAST CANCER. A PHASE 2 STUDY | |||||||||||||
| Medical condition: BREAST CANCER | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-005028-40 | Sponsor Protocol Number: MOLTO | Start Date*: 2019-08-29 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA | |||||||||||||
| Full Title: A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL | |||||||||||||
| Medical condition: Richter syndrome of chronic lymphocytic leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-004851-39 | Sponsor Protocol Number: 109/2006/U/Sper | Start Date*: 2006-10-03 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
| Full Title: A PHASE II, OPEN-LABEL, PROSPECTIVE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBSEQUENT TREATMENT WITH THE ZEVALIN (IBRITUMOMAB TIUXETAN) IN ELDERLY ( 60 YEARS) PATIENTS WITH DI... | |||||||||||||
| Medical condition: DIFFUSE LARGE BCELL LYMPHOMA | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-004850-26 | Sponsor Protocol Number: 108/2006/U/Sper | Start Date*: 2006-10-03 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
| Full Title: A phase II, open-label, prospective, multicenter study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) study in patients with follicular grade ... | |||||||||||||
| Medical condition: follicular grade I-II lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-003884-30 | Sponsor Protocol Number: 117/2007/U/Sper | Start Date*: 2008-03-17 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
| Full Title: Open label, non-randomized, phase II study on fractioned cyclophosphamide, vincristine, liposomal doxorubicin or doxorubicin, and dexamethasone (MY HYPER-CVAD) in the treatment of relapsed refracto... | |||||||||||||
| Medical condition: refractory adult acute lymphoid leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-006832-24 | Sponsor Protocol Number: Z-2021005 | Start Date*: 2022-01-21 |
| Sponsor Name:Ziekenhuis Oost-Limburg A.V. | ||
| Full Title: Heterogeneity, durability and efficacy of the humoral immune response against SARS-CoV-2 (Covid-19) after hospital-wide vaccination | ||
| Medical condition: efficiency and durability of the humoral immune response after vaccination against SARS-CoV-2 | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-001462-17 | Sponsor Protocol Number: WSG-AM06 | Start Date*: 2012-03-29 | |||||||||||
| Sponsor Name:Westdeutsche Studiengruppe GmbH | |||||||||||||
| Full Title: Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer | |||||||||||||
| Medical condition: Early primary breast cancer, hormone receptor positve or negative, HER2 positive or negative, any nodal status. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-006482-16 | Sponsor Protocol Number: EPO2006-AISSM04 | Start Date*: 2007-05-16 | |||||||||||
| Sponsor Name:FISM ONLUS | |||||||||||||
| Full Title: COMPARISON BETWEEN EPOYETIN ALONE ET EPOYETIN ASSOCIATED TO DIFFERENTIATING TERAPY WITH ACID 13-CIS-RETINOICO AND VITAMIN D3 DIIDROXILATED IN MYELODISPLASTIC SYNDROMES WITHOUT BLASTS EXCESS. | |||||||||||||
| Medical condition: MYELODISPLASTIC SYNDROME | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.